Advanced Biomed Inc. Common Stock
Symbol: ADVB (NASDAQ)
Company Description:
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
- Today's Open: $0.354
- Today's High: $0.489
- Today's Low: $0.344
- Today's Volume: 1.22M
- Yesterday Close: $0.3801
- Yesterday High: $0.512
- Yesterday Low: $0.3451
- Yesterday Volume: 12.23M
- Last Min Volume: 6
- Last Min High: $0.367
- Last Min Low: $0.365
- Last Min VWAP: $0.367
- Name: Advanced Biomed Inc. Common Stock
- Website: https://www.advanbiomed.com
- Listed Date: 2025-03-06
- Location: RENO, NV
- Market Status: Active
- CIK Number: 0001941029
- SIC Code: 8071
- SIC description: SERVICES-MEDICAL LABORATORIES
- Market Cap: $7.83M
- Round Lot: 100
- Outstanding Shares: 21.64M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-07-24 | 8-K | View |
2025-07-23 | S-1 | View |
2025-06-06 | 8-K | View |
2025-05-28 | 8-K | View |
2025-05-15 | 10-Q | View |
2025-04-15 | 10-Q | View |
2025-03-10 | 8-K | View |
2025-03-06 | 424B3 | View |
2025-03-06 | 424B4 | View |
2025-03-06 | 424B4 | View |
2025-03-06 | CERT | View |
2025-03-05 | 8-A12B | View |
2025-02-18 | FWP | View |
2025-02-13 | SEC STAFF LETTER | View |
2025-02-11 | EFFECT | View |
2025-02-10 | CORRESP | View |
2025-02-10 | CORRESP | View |
2025-02-07 | S-1/A | View |
2025-01-28 | SEC STAFF LETTER | View |
2025-01-27 | CORRESP | View |